GlassScriptPhysician profile
Chae Miller
NPI 1073050076
$6,518.22
in general payments reported to CMS, 2019-2025
25 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $1,018 · 2023: $1,447 · 2024: $1,675 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,636.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $1,671.99 | 2021-2025 | |
| Ucb, INC. | $1,570.51 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $1,081.99 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $561.81 | 2022-2025 | |
| Aucta Pharmaceuticals, INC. | $219.50 | 2024-2025 | Motpoly Xr |
| Eisai INC. | $218.53 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $167.56 | 2024 | Aptiom |
| Otter Pharmaceuticals, LLC | $159.28 | 2025 | Sympazan |
| Nobelpharma America, LLC | $132.46 | 2023-2025 | |
| Pyros Pharmaceuticals, INC. | $111.35 | 2024 | Vigpoder |
| E.R. Squibb & Sons, L.L.C. | $93.33 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $80.23 | 2021-2023 | Spritam |
| Celgene Corporation | $75.00 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $60.18 | 2023-2024 | Fycompa |
| Azurity Pharmaceuticals, INC. | $50.17 | 2023-2025 | Eprontia, Zonisade |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $41.04 | 2022 | |
| Pfizer INC. | $37.11 | 2024 | |
| Owp Pharmaceuticals, INC. | $31.94 | 2023-2024 | Subvenite, Lamotrigine |
| Supernus Pharmaceuticals, INC. | $29.19 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $27.99 | 2022 | |
| Biomarin Pharmaceutical INC. | $26.14 | 2024 | Brineura |
| Biocodex, INC. | $22.30 | 2025 | |
| Livanova USA, INC. | $20.40 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ptc Therapeutics, INC. | $14.95 | 2023 | |
| Arbor Pharmaceuticals, INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chae Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.